Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Turner

Internal Medicine Calera, AL Medical Doctor

NPI 1700856770 CMS profile 213436

11206 Highway 25, Calera, AL 35040

Open in the dashboard

General payments

$10,733

709 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Turner of Calera, AL is reported in the CMS Open Payments database as having received $10,733 across 709 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,160 61
2024 General $1,576 86
2023 General $1,580 95
2022 General $1,562 111
2021 General $1,738 128
2020 General $1,686 120
2019 General $1,431 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Turner
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Michael Turner were reported at $1,160. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Michael Turner Internal Medicine median Middle half National median
2019 $1,431 $159 $48–$570 $163
2020 $1,686 $119 $33–$402 $114
2021 $1,738 $135 $37–$521 $132
2022 $1,562 $141 $42–$496 $149
2023 $1,580 $149 $45–$519 $160
2024 $1,576 $154 $47–$537 $164
2025 $1,160 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,210 67 payments
  2. AbbVie, Inc. $1,127 93 payments
  3. Janssen Pharmaceuticals, Inc $989 92 payments
  4. GlaxoSmithKline, LLC. $810 59 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $785 50 payments
  6. Novo Nordisk Inc $730 47 payments
  7. Lilly USA, LLC $727 48 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $533 30 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $504 29 payments
  10. Abbott Laboratories $398 20 payments
  11. Other $2,920 174 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,654 705 payments
  2. Gift $59 1 payment
  3. Education $20 3 payments
Products named General payments · program years 2019–2025
  1. XARELTO $984 91 payments
  2. FARXIGA $755 45 payments
  3. XIFAXAN $629 34 payments
  4. TRELEGY ELLIPTA $610 44 payments
  5. Ozempic $586 38 payments
  6. Kerendia $504 29 payments
  7. UBRELVY $489 35 payments
  8. RYBELSUS $435 25 payments
  9. JARDIANCE $399 27 payments
  10. QULIPTA $392 29 payments
  11. Other $7,716 488 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 178 drugs

Part D claims

11,394

Median for Internal Medicine: 777

Drug cost

$1,531,003

Median for Internal Medicine: $73,373

Branded share of claims

27.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 210 $226,783
Mounjaro Tirzepatide Brand 151 $209,729
Ozempic Semaglutide Brand 139 $162,789
Eliquis Apixaban Brand 134 $119,184
Linzess Linaclotide Brand 73 $68,374
Kerendia Finerenone Brand 50 $63,286
Xarelto Rivaroxaban Brand 51 $49,984
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 47 $47,791
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 50 $47,518
Rybelsus Semaglutide Brand 27 $41,305

The 10 drugs with the highest cost, of 178 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$56,209

Of which drugs: $369

Medicare patients

105

Average age 71

Services billed

1,606

49 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 51%
Arthritis 47%
Diabetes 44%
Depression 42%
Ischemic heart disease 41%
COPD 26%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
$145 33 —
UBRELVY
$136 — —
Kerendia
$133 50 —
VRAYLAR
$127 13 —
IBSRELA
$124 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

709 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record